41
Per Hellström, Suad Efendic: Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein. McDermott Will & Emery, February 19, 2002: US06348447 (30 worldwide citation)

The invention relates to the new use of gastrointestinal peptide hormones selected from the class consisting of glucagon-like peptide-1 (GLP-1) and derivatives thereof having anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract for the manufacture of a pharmac ...


42
Glaesner Wolfgang, Millican Rohn Lee Jr, Vick Andrew Mark: Glp-1 analog fusion plroteins. Eli Lilly And Company, Glaesner Wolfgang, Millican Rohn Lee Jr, Vick Andrew Mark, COX Gregory A, January 6, 2005: WO/2005/000892 (30 worldwide citation)

The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions ...


43
Katsu Yasuhiro, Kon I Kana, Morita Mikio, Noguchi Hirohide, Uchida Chikara: N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators. Pfizer Japan, Katsu Yasuhiro, Kon I Kana, Morita Mikio, Noguchi Hirohide, Uchida Chikara, Pfizer, LUMB J Trevor, April 1, 2004: WO/2004/026868 (30 worldwide citation)

This invention provides a compound of the formula (I): wherein Rl represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group in R3 is substituted by at least one substituent selected from the grou ...


44
Chakravarty Prasun K, Fisher Michael H, Parsons William H, Liang Jun, Zhou Bishan: Biaryl substituted 6-membered heterocyles as sodium channel blockers. Merck & Co, Chakravarty Prasun K, Fisher Michael H, Parsons William H, Liang Jun, Zhou Bishan, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, October 7, 2004: WO/2004/084824 (30 worldwide citation)

Biaryl substituted pyridine, pyrimidine and pyrazine compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pha ...


45
Henry C Lin, Mark Pimentel: Methods of treating diarrhea caused by small intestinal bacterial overgrowth. Cedars Sinai Medical Center, Seth D Levy, Davis Wright Tremaine, May 3, 2011: US07935799 (29 worldwide citation)

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of s ...


46
Paul D Rubin, Timothy J Barberich: Methods for treating irritable bowel syndrome using optically pure (+) norcisapride. Sepracor, Pennie & Edmonds, April 9, 2002: US06369079 (29 worldwide citation)

Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythnia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, sub ...


47
Gymer Geoffrey Edward, Kawamura Kiyoshi, Mihara Sachiko, Morita Mikio, Nukui Seiji, Uchida Chikara, Stobie Alan: Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators. Pfizer, July 9, 2003: EP1325921-A2 (29 worldwide citation)

This invention provides compounds of the formula (I) and (II): or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R is hydrogen or halo; R and R are independently hydrogen or C1-6 alkyl; R and R are independently hydrogen or C1-6 alkyl; R is ...


48
Uchida Chikara, Kawamura Kiyoshi: 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders. Pfizer Japan, Uchida Chikara, Kawamura Kiyoshi, Pfizer, FULLER Grover F, October 6, 2005: WO/2005/092882 (28 worldwide citation)

This invention provides a compound of the formula (I): wherein Rl represents a halogen atom; R2 represents a hydrogen atom etc.; R3 represents an alkyl group having from 1 to 4 carbon atoms etc.;R4 represents a hydrogen atom, a hydroxy group, a carboxy group etc.; A represents an oxygen atom etc. or ...


49
Beverley Greenwood Van Meerveld: Spinal cord stimulation as treatment for functional bowel disorders. Oklahoma Foundation for Digestive Research, McAfee & Taft, July 31, 2007: US07251529 (27 worldwide citation)

The present invention relates to treatment of visceral pain of gastrointestinal origin, functional bowel disorders and irritable bowel syndrome comprising electrical stimulation of the spinal cord using one or more commercially available and implantable spinal cord stimulation leads for a time perio ...


50
William D Allen, Margaret A Linggood, Philip Porter: Probiotic. Unilever Patent Holdings, Cushman Darby & Cushman, December 31, 1996: US05589168 (27 worldwide citation)

A novel strain of Enterococcus faecium, deposited as NCIMB 40371, has valuable probiotic properties and is particularly effective in alleviating symptoms of irritable bowel syndrome in human patients. The novel strain can be used in the manufacture of human foodstuffs.



Click the thumbnails below to visualize the patent trend.